293PD_PRRibociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) - Zamagni, C; Campone, M; Kudryavcev, I; Brown-Glaberman, U; Cottu, P H; Ring, A; Lu, J; Martín, M; De Laurentiis, M; Zhou, K; Wu, J; Menon, L; et al.